{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T15:17:16Z","timestamp":1721575036116},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,4]]},"DOI":"10.18632\/oncotarget.15481","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T16:33:37Z","timestamp":1487781217000},"page":"23061-23072","source":"Crossref","is-referenced-by-count":10,"title":["TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML"],"prefix":"10.18632","volume":"8","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria"},{"name":"Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Herndlhofer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria"},{"name":"Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Schneewei\u00df","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Boidol","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ringler","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kubicek","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoline V.","family":"Gleixner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emir","family":"Hadzijusufovic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria"},{"name":"Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria"},{"name":"Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Superti-Furga","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria"},{"name":"Center for Physiology and Pharmacology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Mannhalter","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,18]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Kantarjian","year":"1999","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Barnes","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","article-title":"Chronic myeloid leukemia: a historical perspective","volume":"47","author":"Goldman","year":"2010","journal-title":"Semin Hematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Sawyers","year":"2001","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"Rousselot","year":"2003","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Powell","year":"2006","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy?","volume":"20","author":"Etienne","year":"2014","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Sawyers","year":"2002","journal-title":"Cancer Cell"},{"key":"10","first-page":"S11","article-title":"Resistance and relapse with imatinib in CML: causes and consequences","volume":"6","author":"Deininger","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Sawyers","year":"2004","journal-title":"Science"},{"key":"12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Daley","year":"2005","journal-title":"Cancer Cell"},{"key":"13","first-page":"534","article-title":"New tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"90","author":"Baccarani","year":"2005","journal-title":"Haematologica"},{"key":"14","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Kantarjian","year":"2014","journal-title":"Am J Hematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Michallet","year":"2007","journal-title":"Haematologica"},{"key":"17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Cortes","year":"2008","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"Loriaux","year":"2009","journal-title":"Cancer Cell"},{"key":"20","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Haluska","year":"2012","journal-title":"N Engl J Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Abruzzese","year":"2013","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2013.320","article-title":"Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib","volume":"28","author":"Wolf","year":"2014","journal-title":"Leukemia"},{"key":"23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"le Coutre","year":"2015","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.csbj.2014.08.002","article-title":"Personalized medicine in hematology - A landmark from bench to bed","volume":"10","author":"Badalian-Very","year":"2014","journal-title":"Comput Struct Biotechnol J"},{"key":"25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-1-62703-281-0_4","article-title":"Application of array comparative genomic hybridization in chronic myeloid leukemia","volume":"973","author":"Chung","year":"2013","journal-title":"Methods Mol Biol"},{"key":"26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4238\/2014.February.19.5","article-title":"Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing","volume":"13","author":"Chen","year":"2014","journal-title":"Genet Mol Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ajh.20859","article-title":"Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome","volume":"82","author":"Mill\u00e1","year":"2007","journal-title":"Am J Hematol"},{"key":"28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.24362","article-title":"Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia","volume":"91","author":"D\u00b4Adda","year":"2016","journal-title":"Am J Hematol"},{"key":"29","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-05-0622","article-title":"Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src\/Abl inhibitors are compatible with imatinib","volume":"11","author":"Druker","year":"2005","journal-title":"Clin Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00280-009-1158-7","article-title":"Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells","volume":"66","author":"Topaly","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/156800911793743655","article-title":"Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept","volume":"11","author":"Valent","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"32","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/0008-5472.CAN-12-3678","article-title":"Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications","volume":"73","author":"Eaves","year":"2013","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejca.2011.08.015","article-title":"Quantitative monitoring of BCR\/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia","volume":"48","author":"Lion","year":"2012","journal-title":"Eur J Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ajcp\/101.4.426","article-title":"CD34 immunostaining of bone marrow biopsy specimens is a reliable way to classify the phases of chronic myeloid leukemia","volume":"101","author":"John","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.18632\/oncotarget.101104","article-title":"Standards and impact of hematopathology in myelodysplastic syndromes (MDS)","volume":"1","author":"Ogata","year":"2010","journal-title":"Oncotarget"},{"key":"36","first-page":"1248","article-title":"Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes","volume":"85","author":"Planelles","year":"2000","journal-title":"Haematologica"},{"key":"37","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Lynch","year":"2008","journal-title":"Blood"},{"key":"38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hehlmann","year":"2006","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hehlmann","year":"2002","journal-title":"Leukemia"},{"key":"40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000279442","article-title":"Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition","volume":"127","author":"Shaffer","year":"2009","journal-title":"Cytogenet Genome Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ajcp\/112.1.93","article-title":"Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis","volume":"112","author":"Mannhalter","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"42","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-09-2181","article-title":"Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536","volume":"70","author":"Valent","year":"2010","journal-title":"Cancer Res"},{"key":"43","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Valent","year":"2013","journal-title":"Haematologica"},{"key":"44","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1535-7163.MCT-11-0100","article-title":"An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B","volume":"10","author":"Superti-Furga","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T18:13:57Z","timestamp":1589134437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,18]]},"references-count":45,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,4,4]]}},"alternative-id":["15481","28416739"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15481","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,18]]}}}